OptiNose, Inc. (NASDAQ:OPTN) headquartered in Yardley, will host a conference call for the investment community to discuss the 2Q20 financial results on 4th August 2020 at 8:00 AM Eastern Time.
The conference call will also be webcast live under the investor relations section of the website www.optinose.com
Earnings Expectation
OptiNose, Inc. is expected to report second quarter earnings results, before market open, on Tuesday 4th August 2020. Analysts polled by Thomson Reuters anticipate second quarter loss of $ 0.56 per share. Looking ahead, the full year loss are expected at $ 2.16 per share on the revenues of $ 51.97 million.
OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, and throat; and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary optinose exhalation delivery system that delivers a topically-acting and anti-inflammatory corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps. It also markets Onzetra Xsail (AVP-825) for the acute treatment of migraines in adults through its license agreement with Avanir Pharmaceuticals, Inc.
